HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

Piclozotan

structure in first source

Also Known As:

3-chloro-4-(4-(4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl)butyl)-1,4-benzoxazepin-5(4H)-one; SUN N4057

Networked: 5 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azepines: 11
    - Oxazepines: 5
      - Piclozotan: 5

Experts

1.	Inoue, Teruyoshi: 2 articles (12/2010 - 03/2006)
2.	Koyama, Makoto: 2 articles (12/2010 - 03/2006)
3.	Inoue, T: 2 articles (09/2001 - 02/2001)
4.	Koyama, M: 2 articles (09/2001 - 02/2001)
5.	Ogata, Atsuto: 1 article (12/2010)
6.	Tani, Yoshihiro: 1 article (12/2010)
7.	Barrett, Jeffrey S: 1 article (03/2009)
8.	Fujitani, Tomomichi: 1 article (03/2009)
9.	Mondick, John T: 1 article (03/2009)
10.	Oo, Charles: 1 article (03/2009)

Related Diseases

1.	Hypothermia 09/01/2001 - "[Experimental study of pharmacological hypothermia: enhanced neuroprotective effect of a novel 5-HT 1 A agonist SUN N4057 by the pharmacological hypothermia]."
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 02/26/2001 - "Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1,4-benzoxazepin-5(4H)-one (5: SUN N4057) exhibited remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model." 03/15/2006 - "Among these compounds, 3-chloro-4-[4-[4-(2-pyridinyl)-1,2,3,6-tetrahydropyridin-1-yl]butyl]-1, 4-benzoxazepin-5(4H)-one (50: SUN N4057 (Piclozotan) as 2HCl salt) showed remarkable neuroprotective activity in a transient middle cerebral artery occlusion (t-MCAO) model."
3.	Stroke (Strokes) 03/01/2009 - "A total of 1308 plasma piclozotan concentration measurements from 84 healthy subjects and 412 plasma piclozotan measurements from 74 stroke patients were included in the analysis. "
4.	Parkinson Disease (Parkinson's Disease) 12/15/2010 - "These findings suggest that piclozotan, a serotonin 1A agonist, can improve motor complications in patients with advanced Parkinson's disease." 12/15/2010 - "The effects of piclozotan (SUN N4057) on a rat model of advanced Parkinson's disease were investigated. "
5.	Hyperkinesis 12/15/2010 - "Based on the results of rotational behavior and forelimb hyperkinesia in Week 5, the rats were allocated to three treatment groups (saline and two dosing rates of piclozotan set at 0.018 and 0.036 mg/kg/h). " 12/15/2010 - "Piclozotan (0.018 and 0.036 mg/kg/h, plasma concentrations 5.3±0.7 and 14.3±2.9 ng/ml) reduced levodopa-induced forelimb hyperkinesia by 55% and 69%, respectively, at 1h relative to the control. "

Related Drugs and Biologics

1.	Serotonin (5 Hydroxytryptamine)
2.	Neuroprotective Agents
3.	Piclozotan
4.	Salts
5.	Levodopa (L Dopa)